Mapi - Pharma (Mapi - Pharma) Price-to-Operating-Cash-Flow : (As of Jun. 08, 2024)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Price-to-Operating-Cash-Flow?

As of today (2024-06-08), Mapi - Pharma's share price is $0.00. Mapi - Pharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2015 was $-0.36. Hence, Mapi - Pharma's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Mapi - Pharma's Price-to-Operating-Cash-Flow or its related term are showing as below:

MAPI's Price-to-Operating-Cash-Flow is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 16.11
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Mapi - Pharma's Cash Flow from Operations per share for the six months ended in Jun. 2015 was $0.04. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2015 was $-0.36.

Mapi - Pharma Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Mapi - Pharma's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Price-to-Operating-Cash-Flow Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Price-to-Operating-Cash-Flow

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
Price-to-Operating-Cash-Flow	-	-	-	-	-

Competitive Comparison of Mapi - Pharma's Price-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mapi - Pharma's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's Price-to-Operating-Cash-Flow falls into.

Mapi - Pharma Price-to-Operating-Cash-Flow Calculation

Mapi - Pharma's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.00	/	-0.359
	=

Mapi - Pharma's Share Price of today is $0.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mapi - Pharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2015 was $-0.36.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Mapi - Pharma Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.